Investors often seem to get bored with the actual
execution of business plans, and I think that's at least partly
responsible for the ongoing weakness in Wright Medical (NASDAQ:WMGI) shares. It's also been a weak stretch since early August for many of the company's peers, with Integra (NASDAQ:IART) and Zimmer Biomet (NYSE:ZBH) down as well, and Stryker (NYSE:SYK) just barely up.
Wright
Medical continues to have a strong position in one of the
fastest-growing segments of medical devices, and the company's Augment
biologic has significant growth potential from here. The company has
also largely tied up its hip implant litigation and at a cost that was
within the prior bounds established by management.
Management
has also been delivering successfully against its merger synergy
targets, and I believe the company is on track for strong growth over
the next ten years as new products drive more adoption of upper and
lower extremity procedures. With a fair value in the mid-$20s, Wright
Medical shares still offer worthwhile upside.
Read the full article here:
Wright Medical Checking The Boxes
No comments:
Post a Comment